Search

Displaying results 7481 - 7490 of 10000 in total
  1. Drug

    Carbendazim

    go.drugbank.com/drugs/DB13009
    Investigational

    Carbendazim has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    MBP134

    go.drugbank.com/drugs/DB18686
    Experimental

    MBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).

  3. Drug

    Ataciguat

    go.drugbank.com/drugs/DB12805
    Investigational

    Ataciguat has been investigated for the basic science of Aortic Valve Stenosis.

  4. Drug

    Naftopidil

    go.drugbank.com/drugs/DB12092
    Investigational

    Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.

  5. Drug

    MK-0557

    go.drugbank.com/drugs/DB12168
    Investigational

    MK0557 has been investigated for the treatment of Schizophrenia and Paranoid Schizophrenia.

  6. Drug

    BMS-863233

    go.drugbank.com/drugs/DB12357
    Investigational

    BMS-863233 has been investigated for the treatment of Refractory Hematologic Cancer.

  7. Drug

    Oglemilast

    go.drugbank.com/drugs/DB12375
    Investigational

    Oglemilast has been investigated for the treatment of Pulmonary Disease, Chronic Obstructive.

  8. Drug

    GSK-1292263

    go.drugbank.com/drugs/DB12627
    Investigational

    GSK1292263 has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.

  9. Drug

    MaxAdFVIII

    go.drugbank.com/drugs/DB17713
    Experimental

    MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.

  10. Drug

    EU204

    go.drugbank.com/drugs/DB17438
    Investigational

    EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.